The over-all 3-and 5-year disease free actuarial survival rates were 42% and 33%. 5年生存率为40%25和33%25。
The 1-, 3-, and 5-year actuarial survival rates were 73.3%, 36.6%, 30.0% in the LCAHR group and 60.0%, 26.6%, 20.0% in the CFR group (P<0.05), respectively. 3、5年生存率后程加速超分割组优于常规分割组(P<0.
Purpose To evaluate effect of the biological effective dose(BED) and overall treatment time on the actuarial survival(ASR) and the free from local failure(FLF) incidence of nasopharyngeal carcinoma treated with conventional radiotherapy. 目的探讨鼻咽癌常规分割放疗中等效生物剂量及总疗程时间对局控和生存的影响。